NeuroPace (NPCE) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.57 Bn | 193.97 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 127.25 Bn | 123.77 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.28 Bn | 32.34 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.64 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn | 12.92% |
| 10 | NeuroPace | 462.46 Mn | 410.76 Mn | 18.91 Mn | 24.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -235.17% |
| Dec 31, 2025 | 65.37% |
| Sep 30, 2025 | 12.37% |
| Jun 30, 2025 | -186.41% |
| Mar 31, 2025 | 27.32% |
| Dec 31, 2024 | -210.94% |
| Sep 30, 2024 | 22.83% |
| Jun 30, 2024 | 17.07% |
| Mar 31, 2024 | 5.65% |
| Dec 31, 2023 | 78.14% |
| Sep 30, 2023 | 36.89% |
| Jun 30, 2023 | 26.65% |
| Mar 31, 2023 | 16.58% |
| Dec 31, 2022 | -2.43% |
| Sep 30, 2022 | -47.26% |
| Jun 30, 2022 | -97.63% |
| Mar 31, 2022 | -101.12% |
| Dec 31, 2021 | 77.25% |
| Sep 30, 2021 | -100.43% |
| Jun 30, 2021 | 12.14% |